These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16633998)

  • 1. [Diabetic nephropathy: oral anti-diabetic agents or insulin?].
    Gigante E
    G Ital Nefrol; 2006; 23 Suppl 34():S64-7. PubMed ID: 16633998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin therapy in renal disease.
    Iglesias P; Díez JJ
    Diabetes Obes Metab; 2008 Sep; 10(10):811-23. PubMed ID: 18248491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.
    Snyder RW; Berns JS
    Semin Dial; 2004; 17(5):365-70. PubMed ID: 15461745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats.
    Kim CS; Sohn EJ; Kim YS; Jung DH; Jang DS; Lee YM; Kim DH; Kim JS
    J Ethnopharmacol; 2007 May; 111(2):240-7. PubMed ID: 17194556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P
    Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metformin-associated lactic acidosis].
    Orban JC; Ghaddab A; Chatti O; Ichai C
    Ann Fr Anesth Reanim; 2006 Oct; 25(10):1046-52. PubMed ID: 17005358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J
    Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Insulin requirement in patients with type 1 diabetes with reduced renal function: human insulin versus analogue insulin].
    Hasslacher C; Vogt C; Raupp D; Dreyhaupt J
    Dtsch Med Wochenschr; 2007 Nov; 132(47):2500-4. PubMed ID: 18027324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Insulin analogues: place of detemir (levemir)].
    Dorchy H; Sternon J
    Rev Med Brux; 2006; 27(2):89-94. PubMed ID: 16736846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diabetic nephropathy and prevention of diabetic nephropathy caused chronic renal insufficiency].
    Jakić M; Jakić M; Zibar L; Mihaljević D; Stipanić S; Teskera T
    Lijec Vjesn; 2009; 131(7-8):218-25. PubMed ID: 19769285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.
    Panchapakesan U; Chen XM; Pollock CA
    Nat Clin Pract Nephrol; 2005 Nov; 1(1):33-43. PubMed ID: 16932362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis.
    Monami M; Lamanna C; Marchionni N; Mannucci E
    Exp Clin Endocrinol Diabetes; 2009 May; 117(5):220-2. PubMed ID: 19301231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control.
    Robertson C
    Diabetes Educ; 2006; 32(3):423-32. PubMed ID: 16772658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of advanced glycation end products (AGEs): an implicit goal in clinical medicine for the treatment of diabetic nephropathy?
    Miyata T; Dan T
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S25-9. PubMed ID: 18954918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.